Rory A. Capstick

Discovery of a potent M5 antagonist with improved clearance profile. Part 1: piperidine amide-based antagonists.

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2022, Bioorganic & medicinal chemistry letters.

Development of VU6019650: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M5 Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use Disorder.

Andrew S. Felts, Anna L. Blobaum, N. Schnetz-Boutaud, 2022, Journal of medicinal chemistry.

DARK Classics in Chemical Neuroscience: Gamma-hydroxybutyrate (GHB).

C. Lindsley, Rory A. Capstick, Trevor A Trombley, 2019, ACS chemical neuroscience.

The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu4 PAM development candidate.

Alison R. Gregro, Andrew S. Felts, Anna L. Blobaum, 2019, Bioorganic & medicinal chemistry letters.

VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events.

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2018, ACS medicinal chemistry letters.